Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02165397 (iNNOVATE Study), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia
Who cites it
22 citing papers in PubMed.
- Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.Blood advances · 2026Trial
- Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis.Blood advances · 2025Trial
- Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study.Advances in therapy · 2024Trial
- Continuous or fixed-duration BTK inhibitor treatment for WM.Blood advances · 2026Article
- Article
- Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.Blood advances · 2026Article
- Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain.Therapeutic advances in hematology · 2025Article
- Inhibition of Bruton's tyrosine kinase restricts neuroinflammation following intracerebral hemorrhage.Theranostics · 2025Article
- How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.Blood · 2024Article
- Bruton tyrosine kinase inhibitor-related atrial fibrillation and its implications in the treatment of B-cell lymphoma.Frontiers in cardiovascular medicine · 2024Review
- Optimal use of BTK inhibitors in Waldenström's macroglobulinemia: combination or single drug approach?Therapeutic advances in hematology · 2024Review
- Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.Experimental hematology & oncology · 2023Review
- Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.American journal of hematology · 2023Review
- Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.American journal of hematology · 2023Article
- Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.Journal of clinical medicine · 2023Article
- Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions.Frontiers in oncology · 2023Review
- A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.Current oncology (Toronto, Ont.) · 2022Article
- The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.Clinical hematology international · 2022Review
- The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.Journal of personalized medicine · 2022Review
- Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.Therapeutic advances in hematology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe first report from the open-label substudy of the phase III iNNOVATE study (PCYC-1127; NCT02165397) demonstrated that single-agent ibrutinib was efficacious and well tolerated in patients with heavily pretreated, rituximab-refractory Waldenström macroglobulinemia. Results from the final analysis are now reported. PATIENTS AND
methodsIbrutinib 420 mg was administered once daily to patients (
resultsAfter a median follow-up of 58 months (range: 9-61), median PFS was 39 months [95% confidence interval (CI): 25-not evaluable]; 60-month PFS rate was 40%. In MYD88
conclusionsIn the final analysis from iNNOVATE, single-agent ibrutinib continued to show sustained efficacy in patients with heavily pretreated, rituximab-refractory Waldenström macroglobulinemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.